4,0
19 apr 2025
Dipendente attuale
South San Francisco, CA
Consiglia
Gradimento del CEO
Pronostico commerciale
Vantaggi
Incredible pay and benefits Incredibly smart community of scientists
Svantaggi
My first 3 years were incredible in gRED (the R&D side of Genentech). However the last 3 years have been a series of reorganizations in gRED and the end is nowhere in sight. Layoffs occur regularly and are always looming. It's understandable that changes need to be made because many of our blockbuster drugs have lost exclusivity and we don't have replacements to generate the lost profits (many recent phase 3 failures). However the eternal reorg/layoff cycle is soul crushing after 3 years.